Health AI Central
Share:
Peer-Reviewed Publication
J Am Coll Cardiol2025;86(25):2598-2612.December 23, 2025Journal Article

Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial.

Neal K Lakdawala1, Ray E Hershberger2, Pablo Garcia-Pavia3, Perry Mark Elliott4, Jonathan Ginns5, Benjamin Meder6, Scott Solomon7, Jonathan W Cunningham7, Juan R Gimeno8, Roberto Barriales-Villa9, Eric Adler10, Brenda Gerull11, Naveen L Pereira12, Brian P Halliday13, Wanying Li14, Praneeth Jarugula15, Sonomi Maruyama15, Saffie E Mohran14, Maria Papadaki14, Anu R Anto14, Robert L Anderson14, Hector M Rodriguez14, Carlos L Del Rio14, Jay M Edelberg16, Gregory Kurio17, Juan Maya16, James L Januzzi18
1Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: nlakdawala@bwh.harvard.edu.
2Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
3Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro Majadahonda, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares and Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
4Centre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, London, United Kingdom.
5Austin Heart, Austin, Texas, USA.
6Institute for Cardiomyopathies Heidelberg, Heart Center Heidelberg, University of Heidelberg, Heidelberg, Germany.
7Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
8Inherited Cardiac Disease CSUR/ERN, Hospital Universitario Virgen Arrixaca, Murcia, Spain.
9Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, A Coruña, Spain.
10Department of Medicine, University of California San Diego, San Diego, California, USA.
11Comprehensive Heart Failure Center and Medical Clinic I, University Clinic Würzburg, Würzburg, Germany.
12Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
13Cardiovascular Research Centre, Royal Brompton and Harefield Hospital and National Heart and Lung Institute, Imperial College London, London, United Kingdom.
14Kardigan, South San Francisco, California, USA.
15Bristol Myers Squibb, Princeton, New Jersey, USA.
16Kardigan, Princeton, New Jersey, USA.
17Prolaio, Inc, Chicago, Illinois, USA.
18Massachusetts General Hospital, Harvard Medical School, Baim Institute for Clinical Research, Boston, Massachusetts, USA.
PubMed DOI

Abstract

BACKGROUND: Precision therapies for dilated cardiomyopathy (DCM) are lacking despite diverse manifestations and clinical trajectories based on underlying etiology. DCM-associated pathogenic variants in cardiac beta-myosin heavy chain (MYH7) and titin (TTN) can impair the function/availability of cardiac myosin. Danicamtiv is a novel investigational small molecule that selectively enhances cardiac…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.